Public Release: 

NanoString collaborates with Brigham and Women's Hospital

This collaboration will accelerate translation of genomic discoveries into clinical diagnostics in oncology

Brigham and Women's Hospital

BOSTON and SEATTLE - Oct. 6, 2014 -NanoString Technologies, Inc., (NASDAQ:NSTG) a provider of life science tools for translational research and molecular diagnostic products, today announced that it has signed a multi-year, multi-investigator research collaboration with Harvard-affiliated Brigham and Women's Hospital to accelerate the translation of genomic biomarker discoveries into clinical cancer diagnostics. Using NanoString's Elements™ reagents, assays will be developed to detect gene expression, copy number variations, and fusions from a diverse range of tumor samples.

NanoString's nCounter® Analysis System is an automated and easy-to-use platform that utilizes a novel digital barcoding chemistry to deliver high precision multiplexed assays across a number of important research applications. The research collaboration will enable the researchers at Brigham and Women's Hospital to evaluate and analyze a repository of patient derived tumor tissues for identification of gene signatures and gene expression profiles that typify a specific tumor type. This knowledge is expected to fuel the development of validated diagnostic tests with potential to vastly improve clinical decisions involved in treatment of cancer patients. Under the terms of the agreement, NanoString retains the right to license diagnostic content developed within the scope of the collaboration.

"BWH's ultimate goal is to augment the highest quality care we provide to all our patients," said Jeffrey Golden, MD, chair of the Department of Pathology at BWH. "This collaboration is designed to support not only the discovery of the underlying biology of cancer, but the rapid development of clinical tests. Together we believe we will improve our ability to diagnose, provide better prognostication, improve treatment stratification including qualifications for clinical trials, and conduct biomarker discovery and validation."

"We are excited to partner with Brigham and Women's Hospital to accelerate the process of taking assays the 'last mile' from late stage translational research to clinically-validated assays," said Brad Gray, president and chief executive officer of NanoString Technologies. "This collaboration builds on our growing suite of nCounter Elements offerings by combining Brigham and Women's Hospital's world-class translational research capabilities with NanoString technology to develop robust, highly-multiplexed assays that allow researchers to move genomic discoveries quickly from bench to bedside."

Scott Rodig, MD, is the lead investigator at BWH spearheading the effort with BWH physician colleagues Deborah Dillon, Jon Aster, Michael Kluk, and Neal Lindeman. "Gene-expression profiling is a powerful tool for classifying human tumors that, until recently, has not been amenable to the tissue biopsy specimens analyzed in pathology laboratories," said Rodig. "Further, the work-flow efficiencies of nCounter Elements reagents enable development of highly multiplexed assays for fusion genes and CNVs, offering the potential to develop more efficient, scalable panels than those currently available using FISH or qPCR. This collaboration provides the potential to translate many of the most important discoveries in cancer biology over the last 10 years into the clinic for the first time."


About NanoString Technologies, Inc.

NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company's nCounter® Analysis System has been employed in life sciences research since it was first introduced in 2008 and has been cited in more than 500 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company's technology has now been applied to diagnostic use. The Prosigna® Breast Cancer Prognostic Gene Signature Assay together with the nCounter Dx Analysis System is FDA 510(k) cleared for use as a prognostic indicator for distant recurrence of breast cancer.

For more information, please visit

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the likelihood of this collaboration to translate genomic discoveries to clinical assays, the potential to develop clinical assays using nCounter Elements reagents that will improve diagnosis and decision making with respect to cancer treatments and the use of nCounter Elements reagents to develop panels which are more scalable and efficient than panels using other technologies. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: risks associated with keeping pace with rapidly changing technology and customer requirements; risks regarding the company's ability to successfully introduce new products; risks that new market opportunities may not develop as quickly as expected; risks associated with competition in marketing and selling products; risks of increased regulatory requirements; as well as the other risks set forth in the company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. NanoString Technologies disclaims any obligation to update these forward-looking statements.

The NanoString Technologies logo, NanoString, NanoString Technologies, nCounter Elements and nCounter are either registered trademarks or trademarks of NanoString Technologies, Inc.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.